Gsk (GLAXF) Long-Term Deferred Tax (2009 - 2026)

Gsk's Long-Term Deferred Tax history runs 18 years deep, the most recent figure standing at $8.5 billion for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 5.32% year-over-year to $8.5 billion; the TTM figure through Mar 2026 stood at $8.5 billion (up 5.32% YoY), while the FY2025 annual figure was $8.6 billion, changed 0.47% from the prior year.
• Long-Term Deferred Tax was $8.5 billion for Q1 2026 at Gsk, down from $8.7 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $8.8 billion in Q2 2025 to a low of $421.3 million in Q1 2022.
• Historically, Long-Term Deferred Tax has averaged $7.2 billion across 5 years, with a median of $7.5 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Long-Term Deferred Tax sank 92.91% in 2022, then soared 1518.42% in 2023.
• A 5-year view of Long-Term Deferred Tax shows it stood at $6.6 billion in 2022, then gained by 13.13% to $7.5 billion in 2023, then rose by 15.52% to $8.7 billion in 2024, then gained by 0.0% to $8.7 billion in 2025, then fell by 1.96% to $8.5 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $8.5 billion (Q1 2026), $8.7 billion (Q4 2025), and $8.3 billion (Q3 2025), per Business Quant data.